Affinity-selected heparan sulfate for bone repair

Biomaterials

Volumn 34, Issue 22, 2013, Pages 5594-5605

  Murali, S ^a   Rai, B ^a   Dombrowski, C ^a   Lee, J L J ^a   Lim, Z X H ^a   Bramono, D S ^a   Ling, L ^a   Bell, T ^b   Hinkley, S ^b   Nathan, S S ^c   Hui, J H ^c   Wong, H K ^c   Nurcombe, V ^a   Cool, S M ^a,c  

^a INSTITUTE OF MEDICAL BIOLOGY   (Singapore)

^b CALLAGHAN INNOVATION   (New Zealand)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Bone morphogenetic protein; Bone repair; Glycosaminoglycans; Heparan sulfate

Indexed keywords

BONE MORPHOGENETIC PROTEINS; BONE REPAIR; COST EFFECTIVE; GLYCOSAMINOGLYCANS; GROWTH FACTOR; HEPARAN SULFATES; OSTEOGENESIS; THERAPEUTIC STRATEGY;

BIOACTIVITY; BIOLOGICAL MATERIALS; BONE;

SULFUR COMPOUNDS;

BIOMATERIAL; BONE MORPHOGENETIC PROTEIN 2; COLLAGEN IMPLANT; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; NOGGIN; SMAD PROTEIN; TRANSCRIPTION FACTOR RUNX2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BIOAVAILABILITY; BONE DEFECT; BONE DEVELOPMENT; BONE REMODELING; CONTROLLED STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; RABBIT;

ALKALINE PHOSPHATASE; AMINO ACID SEQUENCE; ANIMALS; ANTICOAGULANTS; BONE AND BONES; BONE MATRIX; BONE MORPHOGENETIC PROTEIN 2; BONE REGENERATION; CALCIFICATION, PHYSIOLOGIC; CARRIER PROTEINS; CELL LINE; CORE BINDING FACTOR ALPHA 1 SUBUNIT; DISACCHARIDES; HEPARITIN SULFATE; HUMANS; MALE; MICE; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; OSTEOGENESIS; PROTEIN STABILITY; RABBITS; TRANSCRIPTION, GENETIC; WOUND HEALING; X-RAY MICROTOMOGRAPHY;

HARNESS; ORYCTOLAGUS CUNICULUS;

EID: 84877599120     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.04.017     Document Type: Article

References (55)

1. Praemer A., Furner S., Rice D.P. Musculoskeletal conditions in the United States 1999, American Academy of Orthopaedic Surgeons, Rosemont, Illinois. 2nd ed.
2. Einhorn T.A. Enhancement of fracture-healing. JBone Jt Surg Am 1995, 77:940-956.
3. Arrington E.D., Smith W.J., Chambers H.G., Bucknell A.L., Davino N.A. Complications of iliac crest bone graft harvesting. Clin Orthop Relat Res 1996, 300-309.
4. Banwart J.C., Asher M.A., Hassanein R.S. Iliac crest bone graft harvest donor site morbidity. A statistical evaluation. Spine (Phila Pa 1976) 1995, 20:1055-1060.
5. Bishop G.B., Einhorn T.A. Current and future clinical applications of bone morphogenetic proteins in orthopaedic trauma surgery. Int Orthop 2007, 31:721-727.
6. Janicki P., Schmidmaier G. What should be the characteristics of the ideal bone graft substitute? Combining scaffolds with growth factors and/or stem cells. Injury 2011, 42(Suppl. 2):S77-S81.
7. Xiao G., Gopalakrishnan R., Jiang D., Reith E., Benson M.D., Franceschi R.T. Bone morphogenetic proteins, extracellular matrix, and mitogen-activated protein kinase signaling pathways are required for osteoblast-specific gene expression and differentiation in MC3T3-E1 cells. JBone Miner Res 2002, 17:101-110.
8. Zou H., Wieser R., Massague J., Niswander L. Distinct roles of type I bone morphogenetic protein receptors in the formation and differentiation of cartilage. Genes Dev 1997, 11:2191-2203.
9. Sipe J.B., Zhang J., Waits C., Skikne B., Garimella R., Anderson H.C. Localization of bone morphogenetic proteins (BMPs)-2, -4, and -6 within megakaryocytes and platelets. Bone 2004, 35:1316-1322.
10. Guo J., Wu G. The signaling and functions of heterodimeric bone morphogenetic proteins. Cytokine Growth Factor Rev 2012, 23:61-67.
11. Ramel M.C., Hill C.S. Spatial regulation of BMP activity. FEBS Lett 2012, 586:1929-1941.
12. Gazzerro E., Gangji V., Canalis E. Bone morphogenetic proteins induce the expression of noggin, which limits their activity in cultured rat osteoblasts. JClin Invest 1998, 102:2106-2114.
13. Gazzerro E., Pereira R.C., Jorgetti V., Olson S., Economides A.N., Canalis E. Skeletal overexpression of gremlin impairs bone formation and causes osteopenia. Endocrinology 2005, 146:655-665.
14. Carragee E.J., Ghanayem A.J., Weiner B.K., Rothman D.J., Bono C.M. Achallenge to integrity in spine publications: years of living dangerously with the promotion of bone growth factors. Spine J 2011, 11:463-468.
15. Carragee E.J., Hurwitz E.L., Weiner B.K. Acritical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J 2011, 11:471-491.
16. Nauth A., Ristiniemi J., McKee M.D., Schemitsch E.H. Bone morphogenetic proteins in open fractures: past, present, future. Injury 2009, 40(Suppl. 3):S27-S31.
17. Takada T., Katagiri T., Ifuku M., Morimura N., Kobayashi M., Hasegawa K., et al. Sulfated polysaccharides enhance the biological activities of bone morphogenetic proteins. JBiol Chem 2003, 278:43229-43235.
18. Jiao X., Billings P.C., O'Connell M.P., Kaplan F.S., Shore E.M., Glaser D.L. Heparan sulfate proteoglycans (HSPGs) modulate BMP2 osteogenic bioactivity in C2C12 cells. JBiol Chem 2007, 282:1080-1086.
19. Bramono D.S., Murali S., Rai B., Ling L., Poh W.T., Lim Z.X., et al. Bone marrow-derived heparan sulfate potentiates the osteogenic activity of bone morphogenetic protein-2 (BMP-2). Bone 2012, 50:954-964.
20. Rai B., Nurcombe V., Cool S.M. Heparan sulfate-based treatments for regenerative medicine. Crit Rev Eukaryot Gene Expr 2011, 21:1-12.
21. Paine-Saunders S., Viviano B.L., Economides A.N., Saunders S. Heparan sulfate proteoglycans retain Noggin at the cell surface: a potential mechanism for shaping bone morphogenetic protein gradients. JBiol Chem 2002, 277:2089-2096.
22. Zhao B., Katagiri T., Toyoda H., Takada T., Yanai T., Fukuda T., et al. Heparin potentiates the invivo ectopic bone formation induced by bone morphogenetic protein-2. JBiol Chem 2006, 281:23246-23253.
23. Bhakta G., Rai B., Lim Z.X., Hui J.H., Stein G.S., van Wijnen A.J., et al. Hyaluronic acid-based hydrogels functionalized with heparin that support controlled release of bioactive BMP-2. Biomaterials 2012, 33:6113-6122.
24. Lee S.S., Huang B.J., Kaltz S.R., Sur S., Newcomb C.J., Stock S.R., et al. Bone regeneration with low dose BMP-2 amplified by biomimetic supramolecular nanofibers within collagen scaffolds. Biomaterials 2013, 34:452-459.
25. Jeon O., Song S.J., Kang S.W., Putnam A.J., Kim B.S. Enhancement of ectopic bone formation by bone morphogenetic protein-2 released from a heparin-conjugated poly(L-lactic-co-glycolic acid) scaffold. Biomaterials 2007, 28:2763-2771.
26. Mazziotti G., Canalis E., Giustina A. Drug-induced osteoporosis: mechanisms and clinical implications. Am J Med 2010, 123:877-884.
27. Danielsson A., Raub E., Lindahl U., Bjork I. Role of ternary complexes, in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa. JBiol Chem 1986, 261:15467-15473.
28. Murphy K.J., Merry C.L., Lyon M., Thompson J.E., Roberts I.S., Gallagher J.T. Anew model for the domain structure of heparan sulfate based on the novel specificity of K5 lyase. JBiol Chem 2004, 279:27239-27245.
29. Lyon M., Gallagher J.T. Bio-specific sequences and domains in heparan sulphate and the regulation of cell growth and adhesion. Matrix Biol 1998, 17:485-493.
30. Park S.H., Silva M., Bahk W.J., McKellop H., Lieberman J.R. Effect of repeated irrigation and debridement on fracture healing in an animal model. JOrthop Res 2002, 20:1197-1204.
31. Song S.J., Hutmacher D., Nurcombe V., Cool S.M. Temporal expression of proteoglycans in the rat limb during bone healing. Gene 2006, 379:92-100.
32. Turnbull J., Powell A., Guimond S. Heparan sulfate: decoding a dynamic multifunctional cell regulator. Trends Cell Biol 2001, 11:75-82.
33. Kuo W.J., Digman M.A., Lander A.D. Heparan sulfate acts as a bone morphogenetic protein coreceptor by facilitating ligand-induced receptor hetero-oligomerization. Mol Biol Cell 2010, 21:4028-4041.
34. Ling L., Murali S., Dombrowski C., Haupt L.M., Stein G.S., van Wijnen A.J., et al. Sulfated glycosaminoglycans mediate the effects of FGF2 on the osteogenic potential of rat calvarial osteoprogenitor cells. JCell Physiol 2006, 209:811-825.
35. Ling L., Murali S., Stein G.S., van Wijnen A.J., Cool S.M. Glycosaminoglycans modulate RANKL-induced osteoclastogenesis. JCell Biochem 2010, 109:1222-1231.
36. Manton K.J., Sadasivam M., Cool S.M., Nurcombe V. Bone-specific heparan sulfates induce osteoblast growth arrest and downregulation of retinoblastoma protein. JCell Physiol 2006, 209:219-229.
37. Murali S., Manton K.J., Tjong V., Su X., Haupt L.M., Cool S.M., et al. Purification and characterization of heparan sulfate from human primary osteoblasts. JCell Biochem 2009, 108:1132-1142.
38. Jackson R.A., Murali S., van Wijnen A.J., Stein G.S., Nurcombe V., Cool S.M. Heparan sulfate regulates the anabolic activity of MC3T3-E1 preosteoblast cells by induction of Runx2. JCell Physiol 2007, 210:38-50.
39. Nurcombe V., Ford M.D., Wildschut J.A., Bartlett P.F. Developmental regulation of neural response to FGF-1 and FGF-2 by heparan sulfate proteoglycan. Science 1993, 260:103-106.
40. Nurcombe V., Goh F.J., Haupt L.M., Murali S., Cool S.M. Temporal and functional changes in glycosaminoglycan expression during osteogenesis. JMol Histol 2007, 38:469-481.
41. Perrimon N., Bernfield M. Specificities of heparan sulphate proteoglycans in developmental processes. Nature 2000, 404:725-728.
42. Ruppert R., Hoffmann E., Sebald W. Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity. Eur J Biochem 1996, 237:295-302.
43. Kim H.J., Kim J.H., Bae S.C., Choi J.Y., Ryoo H.M. The protein kinase C pathway plays a central role in the fibroblast growth factor-stimulated expression and transactivation activity of Runx2. JBiol Chem 2003, 278:319-326.
44. Luong-Van E., Grondahl L., Nurcombe V., Cool S. Invitro biocompatibility and bioactivity of microencapsulated heparan sulfate. Biomaterials 2007, 28:2127-2136.
45. Luong-Van E., Grondahl L., Chua K.N., Leong K.W., Nurcombe V., Cool S.M. Controlled release of heparin from poly(epsilon-caprolactone) electrospun fibers. Biomaterials 2006, 27:2042-2050.
46. Lane J.M., Sandhu H.S. Current approaches to experimental bone grafting. Orthop Clin North Am 1987, 18:213-225.
47. Bostrom M., Lane J.M., Tomin E., Browne M., Berberian W., Turek T., et al. Use of bone morphogenetic protein-2 in the rabbit ulnar nonunion model. Clin Orthop Relat Res 1996, 272-282.
48. Lysaght M.J., Jaklenec A., Deweerd E. Great expectations: private sector activity in tissue engineering, regenerative medicine, and stem cell therapeutics. Tissue Eng Part A 2008, 14:305-315.
49. Place E.S., Evans N.D., Stevens M.M. Complexity in biomaterials for tissue engineering. Nat Mater 2009, 8:457-470.
50. Sanderson R.D., Turnbull J.E., Gallagher J.T., Lander A.D. Fine structure of heparan sulfate regulates syndecan-1 function and cell behavior. JBiol Chem 1994, 269:13100-13106.
51. Katagiri T., Yamaguchi A., Komaki M., Abe E., Takahashi N., Ikeda T., et al. Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. JCell Biol 1994, 127:1755-1766.
52. McKay B., Sandhu H.S. Use of recombinant human bone morphogenetic protein-2 in spinal fusion applications. Spine (Phila Pa 1976) 2002, 27:S66-S85.
53. Zara J.N., Siu R.K., Zhang X., Shen J., Ngo R., Lee M., et al. High doses of bone morphogenetic protein 2 induce structurally abnormal bone and inflammation invivo. Tissue Eng Part A 2011, 17:1389-1399.
54. Woo E.J. Recombinant human bone morphogenetic protein-2: adverse events reported to the manufacturer and user facility device experience database. Spine J 2012, 12:894-899.
55. Murali S., Leong D.F., Lee J.J., Cool S.M., Nurcombe V. Comparative assessment of the effects of gender-specific heparan sulfates on mesenchymal stem cells. JBiol Chem 2011, 286:17755-17765.